AI in Clinical Trials, Moving from Pilot to Scale and the Trust Gap That Still Holds It Back
Dear Clients,
Israeli healthcare and life sciences companies increasingly operate on a global footprint, with clinical development activities, trial sites, vendors, and strategic partners across the United States and Europe.
Against that backdrop, we would like to flag a recent industry discussion on the growing integration of Artificial Intelligence (AI) into clinical trials, and the practical challenge many organizations face when moving from pilots to broader adoption, namely building trust in AI outputs.
As always, the team at Agmon with Tulchinsky remains at your disposal.
More Relevant Media
20.01.2026
Reported Patient Death in an Innovative CRISPR Trial – Client Update – January 2026
Client updates
15.01.2026
Reported Merck Interest in Revolution Medicines – Market Signals for 2026 Biotech M&A Deal Structures and Negotiation Strategy
Client updates
29.12.2025
EU Commission’s Medical Devices Regulation Simplification Proposal and EUDAMED Mandatory Modules Timeline
Client updates
21.07.2025
Amendment to the Medical Information Portability Law, 5784-2024 – Client Update – July 2025
Client updates